File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An update on genomic-guided therapies for pediatric solid tumors

TitleAn update on genomic-guided therapies for pediatric solid tumors
Authors
KeywordsClinical trials on targeted therapies
Pediatric solid tumors
Whole-exome sequencing
Issue Date2017
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon
Citation
Future Oncology, 2017, v. 13 n. 15, p. 1345-1358 How to Cite?
AbstractCurrently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.
Persistent Identifierhttp://hdl.handle.net/10722/263256
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 1.029
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorTsui, PC-
dc.contributor.authorLee, YF-
dc.contributor.authorLiu, ZWY-
dc.contributor.authorIp, LRH-
dc.contributor.authorPiao, W-
dc.contributor.authorChiang, AKS-
dc.contributor.authorLui, VWY-
dc.date.accessioned2018-10-22T07:36:00Z-
dc.date.available2018-10-22T07:36:00Z-
dc.date.issued2017-
dc.identifier.citationFuture Oncology, 2017, v. 13 n. 15, p. 1345-1358-
dc.identifier.issn1479-6694-
dc.identifier.urihttp://hdl.handle.net/10722/263256-
dc.description.abstractCurrently, out of the 82 US FDA-approved targeted therapies for adult cancer treatments, only three are approved for use in children irrespective of their genomic status. Apart from leukemia, only a handful of genomic-based trials involving children with solid tumors are ongoing. Emerging genomic data for pediatric solid tumors may facilitate the development of precision medicine in pediatric patients. Here, we provide an up-to-date review of all reported genomic aberrations in the eight most common pediatric solid tumors with whole-exome sequencing or whole-genome sequencing data (from cBioPortal database, Pediatric Cancer Genome Project, Therapeutically Applicable Research to Generate Effective Treatments) and additional non-whole-exome sequencing studies. Potential druggable events are highlighted and discussed so as to facilitate preclinical and clinical research in this area.-
dc.languageeng-
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon-
dc.relation.ispartofFuture Oncology-
dc.subjectClinical trials on targeted therapies-
dc.subjectPediatric solid tumors-
dc.subjectWhole-exome sequencing-
dc.titleAn update on genomic-guided therapies for pediatric solid tumors-
dc.typeArticle-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.description.naturepostprint-
dc.identifier.doi10.2217/fon-2017-0003-
dc.identifier.pmid28589766-
dc.identifier.scopuseid_2-s2.0-85021401346-
dc.identifier.hkuros295018-
dc.identifier.volume13-
dc.identifier.issue15-
dc.identifier.spage1345-
dc.identifier.epage1358-
dc.identifier.isiWOS:000406288100009-
dc.publisher.placeUnited Kingdom-
dc.identifier.issnl1479-6694-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats